Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)
abacavir/lamivudine/zidovudine
ESS 30005
NCT00038506
Infection, Human Immunodeficiency Virus I
Phase 4
 
January 2014

Powered by ideaPoint, Inc.